Genentech Garners FDA Approval for Tecentriq in Front-Line Lung Cancer Regardless of PD-L1 Status

NEW YORK – Genentech announced on Tuesday that its immunotherapy atezolizumab (Tecentriq) was approved by the US Food and Drug Administration as a first-line option for adult patients with metastatic non-squamous non-small cell lung cancer who don't harbor EGFR or ALK genomic tumor aberrations.